Amgen (AMGN) Goes to Battle Over Knock-Off Biotech Drugs (RHHBY)
Tweet Send to a FriendGet Alerts AMGN Hot Sheet
Price: $104.24 --0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 1.7%
Revenue Growth %: +3.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 1.7%
Revenue Growth %: +3.7%
Trade AMGN Now!
Amgen (Nasdaq: AMGN) shares are higher on the session amid reports that it, along with Roche's (OTCBB: RHHBY) Genentech, is lobbying Washington and multiple states to prevent smaller biotech from producing biosimilar forms of some of its blockbuster drugs.
The two are proposing bills which limit what pharmacists can substitute for brand name products. Proposals have been submitted in eight states this month, the NY Times noted today.
Support seems to be growing, with Virginia's House of Delegates passing one of the bills by a measure of 91 to six.
It's not all about profit though; the companies avow that knock-off forms of the brand name drugs aren't exactly the same, which is why they're called biosimilars rather than generics.
Biosimiar's aren't currently available in the U.S. market, though they have been available in Europe for a number of years. The ongoing battle between the two sides has diminished enthusiasm for companies to enter the biosimilar market, according to the Times. No timeline on when biosimilar makers will be able to sell in the U.S. was given.
Amgen is up 2 percent on the session, while Roche is modestly higher.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The two are proposing bills which limit what pharmacists can substitute for brand name products. Proposals have been submitted in eight states this month, the NY Times noted today.
Support seems to be growing, with Virginia's House of Delegates passing one of the bills by a measure of 91 to six.
It's not all about profit though; the companies avow that knock-off forms of the brand name drugs aren't exactly the same, which is why they're called biosimilars rather than generics.
Biosimiar's aren't currently available in the U.S. market, though they have been available in Europe for a number of years. The ongoing battle between the two sides has diminished enthusiasm for companies to enter the biosimilar market, according to the Times. No timeline on when biosimilar makers will be able to sell in the U.S. was given.
Amgen is up 2 percent on the session, while Roche is modestly higher.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Healthcare Trust of America (HTA) Has Growth Drivers in Sight - Cramer
- EMA Approves MAA for Gilead's (GILD) Sofosbuvir
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
